Dorothée C. B.
- Country
- France
- Department
- Oncology
Research Overview
- A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- TAILORswitch (PADA-2): ctDNA‑guided switch to camizestrant plus abemaciclib in ER‑positive HER2‑negative metastatic breast cancer
- A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease
Data & Insights
Has run more than one trial at 241 of 504 partner sites.
Specializations
Triple Negative Breast Cancer Research
This investigator specializes in advanced therapeutic approaches for triple negative breast cancer (TNBC), with particular focus on combining immunotherapy with neoadjuvant chemotherapy.
- Treatment of early-stage TNBC
- Tumor-infiltrating lymphocyte assessment
- Post-surgical residual disease management
The investigator explores innovative treatment strategies for both pre-operative and post-operative TNBC care.
HER2-Negative Breast Cancer Studies
Focused on developing treatment protocols for HER2-negative breast cancer variants, including evaluation of novel therapeutic agents and combination approaches.
- Primary HER2-negative disease management
- High-risk relapse prevention
- Advanced treatment methodologies
The research encompasses both early-stage and metastatic disease scenarios.
Hormone Receptor-Positive Disease
Expertise in treating estrogen receptor-positive breast cancer, with emphasis on endocrine therapy innovations and targeted treatments.
- Metastatic disease management
- Novel therapeutic combinations
- Advanced endocrine resistance
The investigator evaluates emerging therapeutic options for hormone-dependent breast cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.